<DOC>
	<DOCNO>NCT00004874</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase III trial determine effectiveness monoclonal antibody therapy treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy safety iodine I 131 monoclonal antibody anti-B1 patient relapse refractory , low grade transform low grade B-cell non-Hodgkin 's lymphoma . OUTLINE : On day 1 , patient receive unlabeled monoclonal antibody anti-B1 ( MOAB anti-B1 ) IV 1 hour follow tracer dose iodine I 131 MOAB anti-B1 IV 30 minute determine biodistribution therapeutic dose iodine I 131 MOAB anti-B1 . Patients receive unlabeled MOAB anti-B1 IV 1 hour follow therapeutic dose iodine I 131 MOAB anti-B1 IV 30 minute day 8 . Patients follow week 13 25 every 6 month 2 year . PROJECTED ACCRUAL : Expanded Access Trial , maximum accrual</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapsed refractory , low grade transform low grade Bcell nonHodgkin 's lymphoma include follow : Small lymphocytic Follicular small cleave cell Follicular mix small cleave large cell ( le 50 % large cell component ) Tumor must positive CD20 antigen Relapse disease progression follow least 1 chemotherapy regimen failure achieve objective response ( complete partial response ) prior chemotherapy regimen No disease progression , within 1 year irradiation , arise field previously irradiated 3500 cGy Mean great 25 % intratrabecular marrow space involve lymphoma bilateral iliac crest bone marrow biopsy A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 19 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST le 5 time ULN Renal : Creatinine le 1.5 time ULN No active obstructive hydronephrosis Cardiovascular : No New York Heart Association class III IV heart disease Other : No active infection require IV antibiotic No concurrent illness would preclude evaluation No prior malignancy within past 5 year except adequately treated skin cancer , carcinoma situ cervix , lymphoma HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No prior allergic reaction iodine IV iodine contain contrast material Human antimouse antibody negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy cytokine treatment recover No prior hematologic stem cell transplantation Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( least 6 week since prior nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radioimmunotherapy Surgery : Not specify Other : No concurrent IV antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>